Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note released on Tuesday morning. The brokerage issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Price Performance

Arcadia Biosciences stock opened at $3.60 on Tuesday. The business has a fifty day moving average price of $2.87 and a 200-day moving average price of $2.76. Arcadia Biosciences has a 1-year low of $1.85 and a 1-year high of $4.10. The stock has a market capitalization of $4.90 million, a price-to-earnings ratio of -0.72 and a beta of 1.34.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. The business had revenue of $1.31 million during the quarter, compared to analyst estimates of $0.95 million. During the same period in the prior year, the business posted ($2.64) EPS. On average, equities research analysts anticipate that Arcadia Biosciences will post -1.7 earnings per share for the current fiscal year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.